Literature DB >> 8783754

Results of coeliac disease screening in Estonia in 1990-1994.

O Uibo1, K Metsküla, T Kukk, T Rägo, R Uibo.   

Abstract

In the period of 1990-94, 2895 individuals (629 children with suspicion of coeliac disease selected throughout Estonia; 700 consecutively hospitalized children; 105 children with atopic dermatitis; 1461 inhabitants of a small Estonian town) were serologically screened for coeliac disease. The enzyme-linked immunosorbent assay was used for antigliadin antibody determinations and R1-type antireticulin antibodies were detected using an indirect immunofluorescence method. Coeliac disease was diagnosed according to recent criteria recommended by the European Society for Paediatric Gastroenterology and Nutrition. Antigliadin antibody testing was positive in 44 (3.1%) of 1434 children studied, and in 33 of whom coeliac disease was confirmed. In all the coeliac patients R1-type antireticulin antibody test was positive. However, 52 (3.5%) of 1461 adults studied who did not have coeliac disease had positive antigliadin antibody test but negative antireticulin antibody test. Thus, in Estonia, the antigliadin antibody test can be used in screening for coeliac disease in children but not in adults.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8783754     DOI: 10.1111/j.1651-2227.1996.tb14246.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  2 in total

1.  Nationwide study of childhood celiac disease incidence over a 35-year period in Estonia.

Authors:  Krista Ress; Katrin Luts; Tiina Rägo; Heti Pisarev; Oivi Uibo
Journal:  Eur J Pediatr       Date:  2012-09-18       Impact factor: 3.183

2.  Screening for celiac disease in Down's syndrome patients revealed cases of subtotal villous atrophy without typical for celiac disease HLA-DQ and tissue transglutaminase antibodies.

Authors:  Oivi Uibo; Kaupo Teesalu; Kaja Metskula; Tiia Reimand; Riste Saat; Tarvo Sillat; Koit Reimand; Tiina Talvik; Raivo Uibo
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.